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Introduction. Hypofractionation is an attractive strategy for dose escalation because of the expected increase in the therapeutic
ratio and logistical convenience for patients and radiotherapy departments. Purpose. To report the preliminary results of IMRT
with hypofractionated SIB for prostate cancer. To describe whether dose distributions using SIB are more optimal than sequential
irradiation of the PTVs.
Methods and materials. Prospective analysis of 25 prostate stage T1c-T3N0-1M0. Hypofractionated IMRT with SIB using 6 MV X-ray
were planned to deliver the prescription dose in 29 fractions. We considered an / of 1.5 for prostate and 3 for organs at risk.
PTV, prescription dose–dose/fraction (Gy): prostate 71.05–2.45; seminal vesicles, 52.2–1.8; lymph nodes 52.2–1.8; involved lymph
nodes, 60.9–2.1; overlap prostate-bladder: 65.25–2.25. Prostate dose was equivalent to 80Gy at 2Gy per fraction. Daily imaging
control using 3 ﬁducial markers implanted in the prostate was used. A CBCT was performed on days 1, 7, 15 and 22. Acute and
late toxicity was prospectively scored (RTOG scale). We made a dosimetric comparison of plans using SIB with sequential PTV
irradiation for 1 of the 3 patients with involved nodes.
Results. Acute genitourinary and intestinal toxicity grade ≥2 was observed in 4/25p and 1/25p respectively. At a median follow-up
of 11 (±6.7) months, late intestinal toxicity ≥2 occurred in 1 patient. Two patients had genitourinary grade 1 toxicity. All cases
were disease free. SIB compared to sequential showed similar conformity and heterogeneity index for the PTV above mentioned,
lower doses in the rectum and bladder and lower volume of normal tissues receiving moderate doses.
Conclusions. Hypofractionated IMRT with SIB enables dose escalation with low rates of toxicity. SIB irradiation dosimetric plan is
slightly better than sequential irradiation plans offering an accelerated approach to treat prostate tumours. Longer follow-up is
necessary to evaluate the efﬁcacy and long-term toxicity of hypofractionated treatments.
http://dx.doi.org/10.1016/j.rpor.2013.03.488
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Objective. To report feasibility and evaluate acute toxicity of patients treated with hypofractionation and simultaneous integrated
boost (SIB) with Volumetric Modulated Arc Therapy (VMAT).
Materials/methods. 10 patients with prostate cáncer, were treated for radical intent between March 2012 and October 2012 and all
of whom received androgen suppression. According to D’Amico classiﬁcation, the patients were stratiﬁed in intermediate (60%)
and high risk (40%). On the planning −CT CTV1 and CTV2 were delineated: CTV1 included the prostate, CTV2 consisted on CTV1
plus seminal vesicles. CTVs were expanded (5mm) to generate the planning target volumes (PTV). The prescription was 72Gy to
CTV1 and 60Gy to CTV2. All patients were treated in 30 fractions.
Results.Median agewas 72 andmedianGleason scorewas 7. Themedian follow-upwas 188 days [124–280]. Acute gastro-intestinal
toxicity were: 5/10 Grade G0, 4/10 Grade G1 and 1/10 G2. Genito-urinary toxicity was recorded as follows: 4/10 Grade G0, 5/10 Grade
G1 and 1/10 G2
Conclusions. Moderate hypofractionatioon with SIB and VMAT technique showed to be safe with a good acute toxicity proﬁle.
Longer follow-up and more patients treated with this scheme are needed to assess late toxicity and clinical outcome.
http://dx.doi.org/10.1016/j.rpor.2013.03.489
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Purpose. To present, acute and late toxicity, quality of life (QOL) and early biochemical control of a consecutive series of 69 localized
prostate cancer patients treated with hypofractionated VMAT and IGRT.
Methods. Between May 2011 and June 2012, 69 patients were treated. Doses: 70Gy (2.5Gy/fx) for prostate, 60.2Gy (2.15Gy/fx) for
seminal vesicles and 50.4Gy (1.8Gy/fx) for pelvic lymph nodes. Technique: a single VMAT arc with concomitant boost. IGRT was
made with daily CBCT. Mean patient age was 69.3 yo. Risk group were high 39 (56.5%), intermediate 16 (23.2%) and low 14 (20.3%).
53 patients (77%) were treated with androgenic deprivation. Acute and late toxicity was scored with RTOG criteria, IPSS score
and QoL according manual scoring of QLQC30 and PR25. Biochemical relapse was censored according Phoenix consensus.
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Results. RTOG acute toxicity was GU: G0 9(13%), G1 44(63.7%), G2 14(20,3%), G3 2(3%); GI G0 31(45%), G1 31(45%), G2 7 (11%), G3 0.
RTOG late toxicity was GU G0 46(66.6%), G1 18(26%), G2 4(5.8%), G3 1(1.4%); GI G0 61(88,4%), G1 7(10.1%), G2 1(1.5%). IPSS score: 11
before RT, 16.5 after and 9 at 3 months. Quality of life due to urinary symptoms was better at 3 months. QLQ-C30 global health
status was similar. QLQ-C30 functional scales: slight drop in physical and role functioning. QLQ-C30 symptoms scales: fatigue
and insomnia were slightly higher at 3 months. QLQ-PR25 functional scales of sexual activity and functioning were low in this
population and remained lower at 3 months. QLQ-PR25 symptoms scales: worsening of urinary and bowel symptoms after RT
but with recovery at 3 months. With a medium follow-up of 12 months there is not any biochemical relapse.
Conclusions. Acute and late toxicity of Hypofractionated VMAT-IGRT were light and similar than other series. QLQ impairment
was mild and acceptable. Further following is required to assess long term toxicity and disease control.
http://dx.doi.org/10.1016/j.rpor.2013.03.490
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Introduction. The low value of alfa/beta supports hypofractionated treatment schedules as therapeutic choice for prostate adeno-
carcinoma.
Objective. To explore a hypofractionated scheme as alternative therapeutic choice and demonstrate its potential beneﬁts, dose
escalation to 82Gy, keeping acute toxicity at an acceptable level while shorten the overall treatment length
Methods. In October 2011 our Department implemented a moderate hypofractionation treatment scheme as a new path-
way for prostate adenocarcinoma radiation treatment. Our hypofractionation protocol is based on a fraction dose of 2.6Gy
up to 82Gy 2Gy eq total dose, administered in 27 fractions. To derive the 82Gy isoefect dose “Dhypo” the LQ model was
used. Therefore, Dhypo=D2Gyx(d2Gy+a/b)/(dhypo+a/b) where a/b represents the ratio alfa/beta for prostate adenocarci-
noma. A value a/b=1.5 was selected (Brenner and Hall, 1999) and a/b=6 for normal tissue late reactions for rectum. It
follows Dhypo=82× (2 + 1.5)/(2.6 + 1.5) = 82×0.85=70.0Gy. Rounding off fractions number, the PTV prescribed dose is 70.2Gy,
2.6Gy/fraction, 27 fractions. IMRT dosimetry calculation and treatment administration was performed. Treatment was daily
image guided by Cone Beam CT. Patients were assigned to two study arms, each leaded by a clinician. First group maintained a
standard fractionation while second group scaled to 2.6Gy.
Results. In the period ranging from October 2011 and February 2013, 38 patients underwent daily CBCT image guided IMRT
hypofractionated treatment, 12 low-risk, 10 intermediate-risk and 16 high-risk. Reported RTOG/EORTC toxicity at genitourinary
level was G2:3, G1:16, G0:19. Rectal and intestinal toxicity G1:8, G0:30. Indication of pelvic lymph nodes irradiation for 11 of the 16
high-risk patients with intestinal toxicity G1:6, G0:5. Only one patient required urinary catheterization the last day of treatment
Conclusions. The obtained results show that hypofractionation is a suitable scheme for prostate adenocarcinoma treatment.
Length of treatment is shortened while keeping acute toxicity at a standard fractionation level.
http://dx.doi.org/10.1016/j.rpor.2013.03.491
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Purpose. To assess the impact of magnetic resonance imaging (MRI) staging for patients undergoing High Dose Rate (HDR)
brachytherapy with external beam radiotherapy (EBRT).
Methods and materials. Seventy consecutive patientswith intermediate risk andhigh risk prostate cancer underwent stagingmulti-
parametric MRI (high resolution TSE T2 in axial, sagital and coronal planes including the whole prostate and the seminal vesicles.
TSE T1 axial from pubic symphysis to iliac bifurcation. DWI SS, Volumetric 3D VISTA TSE-T, 3D spectroscopy, MR Perfusion, 3D
FFE T1 Fat Sat after intravenous administration of Gadolinium agent) The MRI ﬁndings were used to guide stage-appropriate
treatment recommendations, and to assist in the preplanning and optimization of the brachytherapy isodose distributions
